Reported Saturday, Kymera's Phase 1b BroADen Data Shows KT-621 Delivers Robust Type 2 Inflammatory Biomarker Reductions And Meaningful Clinical Improvements In Moderate-To-Severe Atopic Dermatitis

Kymera's Phase 1b BroADen trial results indicate that KT-621 significantly reduces Type 2 inflammatory biomarkers and shows meaningful clinical improvements in patients with moderate-to-severe atopic dermatitis. The company is also conducting parallel Phase 2b trials, BROADEN2 for atopic dermatitis and BREADTH for asthma, with data anticipated by mid-2027 and late-2027, respectively.